by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
In the nontransplant setting, continuous therapy may involve a doublet or a triplet regimen as tolerated until disease progression. After the more ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Immunomodulatory drugs act through multiple mechanisms, some of which have yet to be fully characterized. In addition to pairings with proteasome i......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
RVd (lenalidomide, bortezomib, and dexamethasone) continues to represent the standard of care even for older patients, for whom other triplets are ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Pomalidomide-based combinations and anti-CD38–directed therapies are among those that have been shown to be effective in patients with relapsed and......READ MORE
by James R. Berenson, MD; Carol Ann Huff, MD; and Paul G. Richardson, MD
While lenalidomide as maintenance therapy is the strategy for most patients with multiple myeloma, there is ongoing debate about how maintenance th......READ MORE
